The opioid crisis has increased risks for injection drug use-associated HIV outbreaks in rural communities throughout the United States. Existing research has examined pre-exposure prophylaxis (PrEP) utilization among people who inject drugs (PWID); however, no studies have been conducted to explore barriers and facilitators of PrEP use among rural PWID in Appalachia. We conducted qualitative interviews with PWID (n = 48) in two rural counties in West Virginia to explore barriers and facilitators of PrEP use. Among our participants, the majority (68.8%) had never heard of PrEP. Upon learning about PrEP, most participants expressed willingness to use it. Rural PWID described several factors that may impede PrEP utilization (e.g., housing instability, forgetting to take PrEP). Participants also identified practical strategies to support sustained PrEP utilization, such as integrating PrEP services into venues PWID access. This research provides important insights into the barriers and facilitators of PrEP utilization among rural PWID.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Centers for Disease Control and Prevention. HIV among people who inject drugs. https://www.cdc.gov/hiv/group/hiv-idu.html. Accessed 19 Aug 2019.
Centers for Disease Control and Prevention. Lifetime risk of HIV diagnosis: half of black gay men and a quarter of Latino gay men projected to be diagnosed within their lifetime [Press Release]. https://www.cdc.gov/nchhstp/newsroom/2016/croi-press-release-risk.html. Accessed 19 Aug 2019.
Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. 2015;64(26):719–25.
Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.
Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323–31.
Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, et al. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16(1):33.
Havens JR, Oser CB, Leukefeld CG. Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care. 2011;23(5):638–45.
Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17(5):558–65.
Crosby RA, Yarber WL, DiClemente RJ, Wingood GM, Meyerson B. HIV-associated histories, perceptions, and practices among low-income African American women: does rural residence matter? Am J Public Health. 2002;92(4):655–9.
Gamm LD. Mental health and substance abuse services among rural minorities. J Rural Health. 2004;20(3):206–9.
Sung H-E, Mahoney AM, Mellow J. Substance abuse treatment gap among adult parolees: prevalence, correlates, and barriers. Crim Justice Rev. 2011;36(1):40–57.
Sexton RL, Carlson RG, Leukefeld CG, Booth BM. Barriers to formal drug abuse treatment in the rural south: a preliminary ethnographic assessment. J Psychoact Drugs. 2008;40(2):121–9.
Staton-Tindall M, Webster JM, Oser CB, Havens JR, Leukefeld CG. Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women. Soc Work Public Health. 2015;30(4):385–96.
Centers for Disease Control and Prevention. PrEP. https://www.cdc.gov/hiv/basics/prep.html. Accessed 19 Aug 2019.
Centers for Disease Control and Prevention. CDC statement on FDA approval of drug for HIV prevention [Press Release]. https://www.cdc.gov/nchhstp/newsroom/2012/fda-approvesdrugstatement.html. Accessed 19 Aug 2019.
Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed 19 Aug 2019.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
Centers for Disease Control and Prevention. Injection drug use and hiv risk. https://www.cdc.gov/hiv/pdf/risk/cdc-hiv-idu-fact-sheet.pdf. Accessed 12 Dec 2019.
Alpren C, Dawson EL, John B, Cranston K, Panneer N, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.
US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(22):2203–13.
Centers for Disease Control and Prevention. HIV prevention pill not reaching most Americans who could benefit—especially people of color [Press Release]. https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018-PrEP-press-release.html. Accessed 19 Aug 2019.
AIDSVu. Mapping PrEP: first ever data on PrEP users across the U.S. https://aidsvu.org/prep/. Accessed 19 Aug 2019.
Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–700.
Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.
Walters SM, Rivera AV, Starbuck L, Reilly KH, Boldon N, Anderson BJ, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S383–91.
Kuo I, Olsen H, Patrick R, Phillips G 2nd, Magnus M, Opoku J, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.
Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.
Escudero DJ, Kerr T, Wood E, Nguyen P, Lurie MN, Sued O, et al. Acceptability of HIV pre-exposure prophylaxis (PREP) among people who inject drugs (PWID) in a Canadian Setting. AIDS Behav. 2015;19(5):752–7.
Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–91.
Mayer KH, Chan PA, Patel RR, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr. 2018;77(2):119–27.
Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14(1):231.
Ojikutu BO, Bogart LM, Higgins-Biddle M, Dale SK, Allen W, Dominique T, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav. 2018;22(11):3576–87.
Rice WS, Stringer KL, Sohail M, Crockett KB, Atkins GC, Kudroff K, et al. Accessing pre-exposure prophylaxis (PrEP): Perceptions of Current and Potential PrEP Users in Birmingham, Alabama. AIDS Behav. 2019;23:2966–79.
Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.
Bazzi AR, Biancarelli DL, Childs E, Drainoni ML, Edeza A, Salhaney P, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018;32(12):529–37.
US Census Bureau. 2010 Census Urban and Rural Classification and Urban Area Criteria.
Bernard HR, Wutich A, Ryan GW. Analyzing qualitative data: systematic approaches. Thousand oaks: SAGE; 2016.
Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37–46.
Nash B. Cabell County HIV cluster climbs to 53 cases. Huntington Hearld-Dispatch. 2019-06-22. https://www.herald-dispatch.com/news/cabell-county-hiv-cluster-climbs-to-cases/article_0d1f73cc-9491-11e9-8bc2-431f0c058403.html. Accessed 19 Aug 2019.
Allen ST, O’Rourke A, White RH, Schneider KE, Kilkenny M, Sherman SG. Estimating the number of people who inject drugs in a rural county in Appalachia. Am J Public Health. 2019;109(3):445–50.
Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.
Calabrese SK, Earnshaw VA, Underhill K, et al. Prevention paradox: medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. J Int AIDS Soc. 2018;21(6):e25147.
Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016;28(9):1154–8.
Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.
Canary L, Hariri S, Campbell C, Young R, Whitcomb J, Kaufman H, et al. Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States. Clin Infect Dis. 2017;65(3):514–7.
Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR. 2015;64(48):1337–41.
Brown R. Cabell-Huntington Health Department to begin prescribing PrEP to curb spread of HIV. WCHSTV. 2019-04-25. https://wchstv.com/news/local/cabell-huntington-health-department-to-begin-prescribing-prep-to-curb-spread-of-hiv. Accessed 19 Aug 2019.
US Census Bureau. QuickFacts: Cabell County, West Virginia. US Census Bureau, 2018. https://www.census.gov/quickfacts/cabellcountywestvirginia. Accessed 19 Aug 2019.
US Census Bureau. QuickFacts: Kanawha County, West Virginia. US Census Bureau, 2018. https://www.census.gov/quickfacts/kanawhacountywestvirginia. Accessed 19 Aug 2019.
This research was supported by a Grant from the Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health to Dr. Sean T. Allen. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), and by the District of Columbia Center for AIDS Research, an NIH funded program (AI117970). STA and GML are supported by the National Institutes of Health (K01DA046234, K24DA035684). The funders had no role in study design, data collection, or in analysis and interpretation of the results, and this paper does not necessarily reflect views or opinions of the funders. We are grateful to our study participants.
Conflict of interest
Dr. Susan Sherman is an expert witness in ongoing opioid litigation. No other authors have any conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Allen, S.T., O’Rourke, A., White, R.H. et al. Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study. AIDS Behav 24, 1942–1950 (2020). https://doi.org/10.1007/s10461-019-02767-3